At a glance
ClinicalIndex Comparison Record- ✓Pathologically confirmed locally advanced unresectable or metastatic adenocarcinoma of bile ducts, gallbladder, or cholangiocellular carcinoma
- ✓Primary tumors in intrahepatic, hilar, distal bile ducts, or gallbladder
- ✓Aged 18 to 75 years old
- ✓At least one measurable lesion ≥1 cm (spiral CT) or ≥2 cm (plain CT/MRI) per RECIST v1.1
- ✕Disease-free survival within 5 years from other malignancies (except adequately treated basal cell carcinoma or cervical carcinoma in situ)
- ✕Serious or uncontrolled infectious disease (HIV, HBV DNA >500IU/ml)
- ✕Severe uncontrolled acute infection with fever ≥38°C
- ✕Severe hepatic or renal insufficiency
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Second-line Treatment of PD-1 and CTLA-4 Blockade Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma: a Single-arm, Prospective Phase II Trial
In Brief
A Phase 2 clinical trial evaluating Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Cholangiocarcinoma. Currently recruiting, targeting 51 participants across 1 site.
Detailed Summary
This study aimed to evaluate the efficacy and safety of the combination of cadonilimab with liposomal irinotecan plus fluorouracil and leucovorin for the treatment of advanced biliary tract cancer.
Study Details
Timeline
Interventions
cadonilimab at a dosage of 6 mg/kg on day 1 combined with intravenous liposomal irinotecan at a dosage of 70 mg/m2 for 90 min on day 1 plus leucovorin at a dosage of 400 mg/m2 for 30 min on day 1 and fluorouracil at a dosage of 2400 mg/m2 for 46 h every 2 weeks.